Patent ID: 7919520

Claim:
A method of treating a TACE mediated disease in a mammal wherein said TACE mediated disease is rheumatoid arthritis comprising the step of treating said mammal with a compound having formula: or a pharmaceutical composition thereof, wherein: ring A is an optionally substituted 5 membered heterocyclic ring; R x is H, aliphatic, OH, —C(O)—O—(cycloaliphatic or aliphatic or —C(O)—(cycloaliphatic or aliphatic); Ar is an optionally substituted aryl or heteroaryl; X is O, S, NR x , —CH═, —C≡, or CH 2 ; R 1 is C2-C8 alkynyl, optionally substituted with up to 4 substituents selected from halo, Ar, cycloaliphatic, heterocyclyl, NH 2 , NH(cycloaliphatic or aliphatic), N(cycloaliphatic or aliphatic) 2 , halogen, —OH, —O(cycloaliphatic or aliphatic), NO 2 , —CN, —CO 2 H, —CO 2 (cycloaliphatic or aliphatic), —O(halo-cycloaliphatic or aliphatic), or halo-(cycloaliphatic or aliphatic); and wherein up to 2 —CH 2 — in said alkynyl, cycloaliphatic or aliphatic may be replaced with O, S, or —NR x —.